These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21741004)

  • 41. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
    Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
    Pár A; Tornai I; Szalay F
    Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.
    Zhou YQ; Wang XH; Hong GH; Zhu Y; Zhang XQ; Hu YJ; Mao Q
    J Viral Hepat; 2011 Aug; 18(8):595-600. PubMed ID: 21105968
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?
    Cross TJ; Quaglia A; Nolan J; Hughes S; Harrison PM
    J Med Virol; 2010 May; 82(6):958-64. PubMed ID: 20419809
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients].
    Liu JP; Kang Y; Shang J; Ding GQ; Xiao EH; Wei JF; Cao Q
    Zhonghua Gan Zang Bing Za Zhi; 2013 Sep; 21(9):656-8. PubMed ID: 24160338
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection.
    Potthoff A; Wedemeyer H; Boecher WO; Berg T; Zeuzem S; Arnold J; Spengler U; Gruengreiff K; Kaeser T; Schuchmann M; Bergk A; Forestier N; Deterding K; Manns MP; Trautwein C;
    J Hepatol; 2008 Nov; 49(5):688-94. PubMed ID: 18490077
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C.
    Males S; Gad RR; Esmat G; Abobakr H; Anwar M; Rekacewicz C; El Hoseiny M; Zalata K; Abdel-Hamid M; Bedossa P; Pol S; Mohamed MK; Fontanet A
    Antivir Ther; 2007; 12(5):797-803. PubMed ID: 17713163
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C.
    Coban S; Idilman R; Erden E; Tüzün A
    Hepatogastroenterology; 2011; 58(109):1301-6. PubMed ID: 21937399
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment.
    Zignego AL; Cozzi A; Carpenedo R; Giannini C; Rosselli M; Biagioli T; Aldinucci A; Laffi G; Moroni F
    Dig Liver Dis; 2007 Sep; 39 Suppl 1():S107-11. PubMed ID: 17936210
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The interrelation between lipid profile in chronic HCV patients and their response to antiviral agents.
    Eletreby R; Anees M; Naguib M; Kobtan A; Helmy A; Khalaf N; Mansour S; Hassany M; El Akel W; Hashem A; Doss W; Esmat G
    Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):103-110. PubMed ID: 32933323
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.
    Meissner EG; Lee YJ; Osinusi A; Sims Z; Qin J; Sturdevant D; McHutchison J; Subramanian M; Sampson M; Naggie S; Patel K; Remaley AT; Masur H; Kottilil S
    Hepatology; 2015 Mar; 61(3):790-801. PubMed ID: 25203718
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up.
    Corey KE; Kane E; Munroe C; Barlow LL; Zheng H; Chung RT
    Hepatology; 2009 Oct; 50(4):1030-7. PubMed ID: 19787818
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The association of hepatitis c virus infection status with serum glucose levels.
    Li Y; Wang X; Yu G; Sun H; Lv J; Chi X; Wu R; Gao X; Niu J
    BMC Gastroenterol; 2019 Jun; 19(1):86. PubMed ID: 31195990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens.
    Carvalho JR; Velosa J; Serejo F
    Scand J Gastroenterol; 2018; 53(7):857-863. PubMed ID: 29779403
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study.
    Lee H; Chien RN; Pao LH; Kuo CJ; Huang PH; Chang ML
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831156
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recovery of lipid metabolic alterations in hepatitis C patients after viral clearance: Incomplete restoration with accelerated ω-oxidation.
    Chang SW; Cheng ML; Shiao MS; Yeh CT; Wang CH; Fan CM; Chiu CT; Chang ML
    J Clin Lipidol; 2018; 12(3):756-766. PubMed ID: 29574072
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exploring lipid and apolipoprotein levels in chronic hepatitis C patients according to their response to antiviral treatment.
    Lacerda GS; Medeiros T; Rosário NFD; Peralta RHS; Cabral-Castro MJ; Esberard EBC; Andrade TG; Xavier AR; Silva AA
    Clin Biochem; 2018 Sep; 60():17-23. PubMed ID: 30030979
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sexual Dimorphic Metabolic Alterations in Hepatitis C Virus-infected Patients: A Community-Based Study in a Hepatitis B/Hepatitis C Virus Hyperendemic Area.
    Hu JH; Chen MY; Yeh CT; Lin HS; Lin MS; Huang TJ; Chang ML
    Medicine (Baltimore); 2016 May; 95(18):e3546. PubMed ID: 27149466
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of Chronic Hepatitis C Virus Genotype 1b Infection on Triglyceride Concentration in Serum Lipoprotein Fractions.
    Nagano T; Seki N; Tomita Y; Sugita T; Aida Y; Itagaki M; Sutoh S; Abe H; Tsubota A; Aizawa Y
    Int J Mol Sci; 2015 Aug; 16(9):20576-94. PubMed ID: 26334270
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of depression in patients with chronic hepatitis: effect of interferon treatment.
    Koskinas J; Merkouraki P; Manesis E; Hadziyannis S
    Dig Dis; 2002; 20(3-4):284-8. PubMed ID: 12577943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.